Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teriparatide injection - Eli Lilly

Next Previous
X
Search
Drug Profile

Teriparatide injection - Eli Lilly

Alternative Names: Forsteo; Forteo; hPTH 1-34; LY 333334; MN 10T; Parathar; Parathyroid hormone (1-34); PTH; Teriparatide; Teriparatide acetate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Eli Lilly; Eli Lilly and Company
  • Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis
  • Market Withdrawal Hypoparathyroidism
  • Discontinued Fracture

Most Recent Events

  • 18 Feb 2022 Eli Lilly's formulation and use patents for teriparatide injection expires in major markets
  • 31 Mar 2020 Nagasaki University Hospital completes a clinical trial for Osteoporosis (In the elderly) in Japan (UMIN000020584)
  • 09 Jul 2019 Discontinued - Phase-III for Fracture treatment in South America, Spain, Sweden, Canada, Norway, Lithuania, Latvia, Hong Kong, Finland, Estonia, Denmark, Switzerland, Romania, Japan, Taiwan, Poland, Netherlands, India, Hungary, Greece, Germany, France, Croatia, Turkey, Israel, New Zealand, Australia, South Korea, Belgium, USA (SC) (Eli Lilly pipeline, July 2019)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top